Log In
BCIQ
Print this Print this
 

R256

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionInhaled interleukin-13 (IL-13) signaling and janus kinase (JAK) inhibitor
Molecular Target Interleukin-13 (IL-13) ; Janus kinase (JAK)
Mechanism of ActionJanus kinase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationAsthma
Indication DetailsTreat chronic asthma
Regulatory Designation
PartnerAstraZeneca plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$100.0M

$1.0M

$99.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/25/2012

$100.0M

$1.0M

$99.0M

Get a free BioCentury trial today